Tvardi Therapeutics is a clinical-stage, private biotechnology company based in Houston, Texas. They specialize in developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases, and fibrotic diseases. With a focus on inhibitors of STAT3, a key signaling molecule, Tvardi aims to target the gene networks that control the survival and immune sequestration of cancer cells, as well as the pathogenesis of various inflammatory and fibrotic conditions.

Led by a team of experienced entrepreneurs, innovative scientists, and dedicated physicians, Tvardi is at the forefront of advancing medical treatments. Their lead product, TTI-101, is currently undergoing clinical trials and has shown promising results in terms of safety and clinical activity. Tvardi Therapeutics recognizes the significant societal and economic impact of STAT3-dependent diseases.

They are committed to developing safe and effective small molecule inhibitors of STAT3 that can be used to combat a range of diseases. For cutting-edge therapeutic solutions that revolutionize cancer treatment and address chronic inflammatory and fibrotic diseases, trust Tvardi Therapeutics